Cargando…

Herbal NF-κB Inhibitors Sensitize Rituximab-Resistant B Lymphoma Cells to Complement-Mediated Cytolysis

BACKGROUND: Drug resistance remains a serious challenge to rituximab therapy in B-NHL (B cell non-Hodgkin’s lymphoma). CDC (complement-dependent cytotoxicity) has been proposed as a major antitumor mechanism of rituximab, and direct abrogation of CD59 function partially restores rituximab sensitivit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ge, Xiaowen, Du, Yiqun, Chen, Jianfeng, Zhu, Na, Yao, Jiamei, Zhang, Xin, Wang, Na, Sun, Yujing, Gao, Feng, Hu, Weiguo, Hou, Yingyong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8692258/ https://www.ncbi.nlm.nih.gov/pubmed/34956875 http://dx.doi.org/10.3389/fonc.2021.751904

Ejemplares similares

Midostaurin potentiates rituximab antitumor activity in Burkitt’s lymphoma by inducing apoptosis
por: Ge, Xiaowen, et al.
Publicado: (2018)

NF-κB fingerprinting reveals heterogeneous NF-κB composition in diffuse large B-cell lymphoma
por: Jayawant, Eleanor, et al.
Publicado: (2023)

NF-κB Mutations in Germinal Center B-Cell Lymphomas: Relation to NF-κB Function in Normal B Cells
por: Pasqualucci, Laura, et al.
Publicado: (2022)

Complement and complement regulatory proteins are upregulated in lungs of COVID-19 patients
por: Ge, Xiaowen, et al.
Publicado: (2023)

S100B immunization triggers NFκB and complement activation in an autoimmune glaucoma model
por: Reinehr, Sabrina, et al.
Publicado: (2018)

Gemcitabine enhances rituximab‐mediated complement‐dependent cytotoxicity to B cell lymphoma by CD20 upregulation
por: Hayashi, Kazumi, et al.
Publicado: (2016)

Primary breast diffuse large B-cell lymphoma in the era of rituximab
por: Zhang, Na, et al.
Publicado: (2016)

Exploring complement-dependent cytotoxicity by rituximab isotypes in 2D and 3D-cultured B-cell lymphoma
por: Lara, Sandra, et al.
Publicado: (2022)

Downregulation of miR‐1225‐5p is pivotal for proliferation, invasion, and migration of HCC cells through NFκB regulation
por: Liu, Lin, et al.
Publicado: (2020)

Zhuanggu Guanjie herbal formula mitigates osteoarthritis via the NF-κB transduction mechanism
por: Guowei, Gong, et al.
Publicado: (2022)

Rituximab maintenance therapy for patients with diffuse large B-cell lymphoma: A meta-analysis
por: Zhou, Xuan, et al.
Publicado: (2017)

Characterizing the role of the alternative NF-κB pathway in diffuse large B-cell lymphoma
por: Ito, Daisuke, et al.
Publicado: (2013)

Deregulated Levels of the NF-κB1, NF-κB2, and Rel Genes in Ukrainian Patients with Leukemia and Lymphoma in the Post-Chernobyl Period
por: Savlı, Hakan, et al.
Publicado: (2016)

The RCAN1 inhibits NF-κB and suppresses lymphoma growth in mice
por: Liu, C, et al.
Publicado: (2015)

NF-κB signaling and its relevance to the treatment of mantle cell lymphoma
por: Balaji, Swathi, et al.
Publicado: (2018)

NF-κB and Disease
por: Poma, Paola
Publicado: (2020)

Monitoring of the Complement System Status in Patients With B-Cell Malignancies Treated With Rituximab
por: Felberg, Anna, et al.
Publicado: (2020)

Energy metabolism and T-cell-mediated cytolysis. II. Selective inhibition of cytolysis by 2-deoxy-D-glucose
Publicado: (1977)

NF-κB Members Left Home: NF-κB-Independent Roles in Cancer
por: Colomer, Carlota, et al.
Publicado: (2017)

PI3K/AKT inhibition reverses R-CHOP resistance by destabilizing SOX2 in diffuse large B cell lymphoma
por: Chen, Jianfeng, et al.
Publicado: (2020)

Effect of membrane-bound complement regulatory proteins on tumor cell sensitivity to complement-dependent cytolysis triggered by heterologous expression of the α-gal xenoantigen
por: Wang, Yu, et al.
Publicado: (2018)

Cytolysis of fibroblasts by C3a.
por: Temple, A., et al.
Publicado: (1980)

Nanoencapsulated rituximab mediates superior cellular immunity against metastatic B-cell lymphoma in a complement competent humanized mouse model
por: Wen, Jing, et al.
Publicado: (2021)

Blocking Autophagy Prevents Bortezomib-Induced NF-κB Activation by Reducing I-κBα Degradation in Lymphoma Cells
por: Jia, Li, et al.
Publicado: (2012)

Analysis of variation in NF-κB genes and expression levels of NF-κB-regulated molecules
por: Liu-Mares, Wen, et al.
Publicado: (2007)

B cell non-Hodgkin's lymphoma: rituximab safety experience
por: Mohrbacher, Ann
Publicado: (2005)

Intralesional rituximab for cutaneous manifestations of systemic B-cell lymphoma
por: Maillet-Lebel, Nicole, et al.
Publicado: (2016)

Intervention of NF-Κb Signaling Pathway and Preventing Post-Operative Cognitive Dysfunction as Well as Neuronal Apoptosis
por: Yuan, Na, et al.
Publicado: (2022)

NF-κB and the Immunoglobulin κ Gene Enhancer
por: Sen, Ranjan
Publicado: (2004)

Keeping NF-κB in check
por: Williams, Ruth
Publicado: (2006)

At the crossroads of SUMO and NF-κB
por: Kracklauer, Martin P, et al.
Publicado: (2003)

Slow but steady for NF-κB
por: Leslie, Mitch
Publicado: (2012)

NF-κB in premature aging
por: Osorio, Fernando G., et al.
Publicado: (2012)

Hypoxia Induced NF-κB
por: D’Ignazio, Laura, et al.
Publicado: (2016)

NF-κB signaling in inflammation
por: Liu, Ting, et al.
Publicado: (2017)

Noncanonical NF-κB in Cancer
por: Tegowski, Matthew, et al.
Publicado: (2018)

NFκB and Kidney Injury
por: Song, Ning, et al.
Publicado: (2019)

NF-κB in Hematological Malignancies
por: Imbert, Véronique, et al.
Publicado: (2017)

NF-κB Signalling in Glioblastoma
por: Soubannier, Vincent, et al.
Publicado: (2017)

Increased α-HB links colorectal cancer and diabetes by potentiating NF-κB signaling
por: Lv, Xinyue, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_j8h2e88mgec1r7a80m0hvm2chl